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Regulation of ARNO nucleotide exchange by a PH domain
electrostatic switch
Lorraine C. Santy*, Scott R. Frank*†, Jessica C. Hatfield*
and James E. Casanova*‡§
ARNO is a member of a family of guanine nucleotide
exchange factors that activate small GTPases called
ADP-ribosylation factors (ARFs) [1–3], which regulate
vesicular trafficking and, in one case (ARF6), also
regulate cortical actin structure [4]. ARNO is located at
the plasma membrane, and in the presence of activated
protein kinase C (PKC) can induce cortical actin
rearrangements reminiscent of those produced by
active ARF6 [5–8]. High-affinity binding of ARNO to
membranes, which is required for exchange activity, is
mediated cooperatively by a pleckstrin homology (PH)
domain and an adjacent carboxy-terminal polybasic
domain [3,9]. ARNO is phosphorylated in vivo by PKC
on a single serine residue, S392, located within the
carboxy-terminal polybasic domain. Mutation of S392 to
alanine does not prevent ARNO-mediated actin
rearrangements, suggesting that phosphorylation does
not lead to ARNO activation [6]. Here, we report that
phosphorylation negatively regulates ARNO exchange
activity through a ‘PH domain electrostatic switch’.
Introduction of a negatively charged phosphate into the
polybasic domain reduced interaction of ARNO with
membranes both in vitro and in vivo, and inhibited
exchange in vitro. This regulated membrane association
is similar to the myristoyl electrostatic switch that
controls membrane binding of the myristoylated
alanine-rich C kinase substrate (MARCKS) [10], but to
our knowledge is the first demonstration of an
electrostatic switch regulating the membrane
interaction of a protein containing a PH domain. This
mechanism allows regulation of ARNO lipid binding
and exchange activity at two levels, phosphoinositide-
dependent recruitment and PKC-dependent
displacement from the membrane.
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Results and discussion
We have shown previously that ARNO is phosphorylated
within its polybasic domain. Because this domain con-
tributes to membrane lipid binding [9], we hypothesized
that phosphorylation might inhibit ARNO activity by dis-
placing it from the membrane. To test this hypothesis, we
measured the effect of ARNO phosphorylation on its
nucleotide exchange activity in vitro. Nucleotide exchange
was assayed in the presence of unilamellar phospholipid
vesicles containing either a mixture of phosphatidylcholine
(PC) and phosphatidylserine (PS), or the same lipids sup-
plemented with phosphatidylinositol 4,5-bisphosphate
(PI(4,5)P2). As shown previously [11], ARNO activity was
dramatically enhanced in the presence of polyphospho-
inositides, as little exchange activity was detected in the
absence of this lipid (Figure 1). Exchange occurred in the
presence of liposomes containing either PI(4,5)P2
(EC50 = 0.4%) or phosphatidylinositol 3,4,5-trisphosphate
(PI(3,4,5)P3, EC50 = 0.025%; data not shown). 
The effect of ARNO phosphorylation on nucleotide
exchange activity was tested by incubating ARNO with
PKC in the presence or absence of ATP.  Phosphorylated
ARNO exhibited significantly reduced exchange activity
compared with non-phosphorylated ARNO (Figure 1a).
Nevertheless, ARNO exchange activity was not com-
pletely inhibited by phosphorylation, which could be
because of incomplete phosphorylation of ARNO by PKC
under these conditions. To test this possibility, we
replaced the S392 residue with  glutamic acid (S392E),
thereby producing a protein with a permanent negative
charge at this position. The S392E mutant had negligible
exchange activity (Figure 1b), suggesting that the residual
activity exhibited by phosphorylated ARNO is due to
incomplete phosphorylation.
Binding of ARNO to membranes is mediated coopera-
tively by the PH domain, which binds to polyphospho-
inositides, and the polybasic domain, which interacts
electrostatically with acidic phospholipids [3,9]. This
arrangement of lipid-binding domains is reminiscent of
the domain structure of other proteins, such as Src and
MARCKS [12,13]. These proteins contain a covalently
attached myristoyl group, which inserts into the hydropho-
bic interior of the membrane bilayer, and a positively
charged subdomain that interacts electrostatically with
acidic phospholipids [12,13]. The basic region of
MARCKS contains multiple sites for PKC phosphoryla-
tion, and introduction of negatively charged phosphates
into the basic domain abrogates interaction of this domain
with the membrane [13,14]. Phosphorylation of MARCKS
thus leads to translocation of this protein from the mem-
brane to the cytosol [14]. This mechanism of regulated
membrane association has been referred to as a myristoyl
electrostatic switch [10]. 
To investigate whether phosphorylation of S392 inhibits
ARNO exchange activity by reducing ARNO lipid
binding, we examined the binding of ARNO in vitro to
liposomes containing [3H]PC as a tracer. Binding of
ARNO to liposomes was dependent on the presence of
phosphoinositides in the liposomes and a functional
PH domain in ARNO (data not shown). We tested for
the presence of an electrostatic switch by incubating
recombinant ARNO and liposomes with PKC in the
presence or absence of ATP. As shown in Figure 2a,
incubation of wild-type ARNO with PKC and ATP
reduced the binding of ARNO to liposomes by 90%. In
contrast, incubation of the S392A ARNO mutant with
PKC and ATP had little effect on the ability of the
recombinant protein to bind liposomes, ruling out any
indirect effects of either the kinase or ATP on
ARNO–lipid interactions. The S392E mutation also dis-
rupted binding of ARNO to liposomes (Figure 2a).
Similar results were obtained when liposomes contained
PI(3,4,5)P3 instead of PI(4,5)P2 (Figure 2b). Taken
together, these results support the hypothesis that intro-
duction of a negatively charged phosphate group at posi-
tion 392 is sufficient to destabilize the association of
ARNO with the membrane in vitro.
To determine whether phosphorylation regulates the asso-
ciation of ARNO with membranes in vivo, we examined
the distribution of phosphorylated ARNO in metabolically
labeled cells. Cells expressing Myc-epitope-tagged wild-
type ARNO (Myc–ARNO) were labeled with
32P-orthophosphate as described in the Materials and
methods section and incubated either with or without
500 nM phorbol 12-myristate 13-acetate (PMA) to activate
PKC. Immunoblot analysis indicated that Myc–ARNO
partitioned into cytosolic and membrane-associated pools
(Figure 3a, upper panel), as has been reported for endoge-
nous ARNO [5]. Little phosphorylated ARNO is detected
in either fraction in the absence of PMA (Figure 3a, lower
panel). Upon PMA treatment, however, phosphorylated
ARNO was readily detectable and, importantly, was selec-
tively accumulated in the cytosol. Although a significant
fraction of the total ARNO remained associated with
membranes in the presence of PMA, this pool was not
phosphorylated. As PKC is thought to function only at
membrane surfaces, these data suggest that ARNO is
phosphorylated while membrane-bound and that phos-
phorylation induces its translocation to the cytosol. 
The effect of a negative charge on lipid binding in vivo
was confirmed by comparing the localization of ARNO
mutants lacking the coiled-coil domain in the presence or
absence of the S392E mutation. Membrane association of
the S392E mutant was reduced approximately 75% rela-
tive to the control, but binding of ARNO to membranes
was not completely eliminated by the S392E mutation
(Figure 3b). There are several possible explanations. In
addition to binding lipid, ARNO may also interact with
other membrane-bound proteins. Alternatively, it must be
recalled that the S392E mutant retains an intact PH
domain. The PH domain of cytohesin-1 in the absence of
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Figure 1
Phosphorylation of ARNO by PKC inhibits nucleotide exchange activity
towards ARF6. (a) After incubation of ARNO with PKC in the absence
or presence of ATP, ARNO exchange activity on ARF6 was assayed as
described in the Materials and methods. (b) A negative charge at
position 392 inhibits ARNO exchange activity. Wild-type ARNO and
the S392E ARNO mutant were tested for exchange activity as
described in the Materials and methods. In (a,b), negligible exchange
activity was seen in the absence of ARNO or when liposomes lacking
PI(4,5)P2 were used in the exchange assay. Data shown are
mean ± SEM of triplicate samples.
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Figure 2
PKC-mediated phosphorylation of ARNO at S392 inhibits binding of
ARNO to liposomes. Binding of ARNO to liposomes containing
(a) PI(4,5)P2 or (b) PI(3,4,5)P3. ARNO (5 µg), liposomes (0.4 mg/ml)
and PKC were incubated in the absence or presence of ATP, and the
ARNO–liposome complexes isolated and quantitated as described in
the Materials and methods section. Binding of the S392E mutant was
tested only in the absence of ATP. Data shown are mean ± SD of
triplicate samples and are representative of four experiments.
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the polybasic domain retains the ability to bind lipid,
although with greatly reduced affinity compared with the
intact protein [9]. Therefore, although introduction of
negative charge into the polybasic domain clearly reduces
membrane association, at the levels of expression seen in
transiently transfected cells a fraction of the protein might
still associate with the membrane.
Several recent studies have indicated that ARNO [15]
and its relatives cytohesin-1 [16] and GRP1 [17] can be
recruited to the plasma membrane by signals leading to
the activation of phosphoinositide (PI) 3-kinase. In each
case, the recruitment could be inhibited by the PI
3-kinase inhibitors wortmannin or LY294002, suggesting
that D3 phosphoinositides are required for membrane
recruitment of these proteins. ARNO can, however, be
recruited to actin-rich membrane ruffles by treatment of
cells with PMA in a manner that is not inhibited by wort-
mannin [6]. The most probable explanation is that PKC
activation increases availability of PI(4,5)P2-binding sites,
either through de novo synthesis [18] or by unmasking of
pre-existing sites (for example, by displacement of
MARCKS) [19]. This recruitment does not require
ARNO phosphorylation [6]. It is probable, therefore, that
recruitment and phosphorylation are sequential events,
phosphorylation occurring only after interaction of ARNO
with the membrane.
Regardless of whether ARNO is bound through PI(4,5)P2
or PI(3,4,5)P3 in vivo, our data indicate that phosphoryla-
tion within the carboxy-terminal polybasic region dramati-
cally reduces the affinity of the protein for membranes
containing acidic phospholipids (PS) and either phospho-
inositide in vitro. Additionally, we have shown that phos-
phorylated ARNO is exclusively cytosolic in vivo, and
introduction of a negative charge into the polybasic
domain reduces membrane association. Phosphorylation of
ARNO by PKC might therefore represent an additional
mechanism by which ARNO (and, subsequently, ARF)
activation is tightly regulated. In such a model, production
or unmasking of polyphosphoinositides would lead to
ARNO membrane recruitment and activation of ARF.
Although we have suggested that ARF6 is the primary
substrate for ARNO because of its plasma-membrane
localization, other ARFs would also be potential substrates
provided they can localize to the plasma membrane. Phos-
phorylation of ARNO at the plasma membrane would
then terminate the activating signal, resulting in a short
burst of ARF activation. As PI 3-kinase activation is not
always coupled to PKC activation, it is possible that the
duration of the ARF signal might depend on the specific
signaling pathway through which ARNO is recruited.
It is also interesting to note that the other members of the
ARNO family of GEFs differ in the number of potential
phosphorylation sites within the polybasic domain.
Although ARNO contains a single serine residue in this
region, cytohesin-1 has two serines and a threonine in
potential PKC phosphorylation sites, and GRP-1 lacks any
potential phosphorylation sites within the basic domain
[6]. This suggests that ARNO and cytohesin-1 can be reg-
ulated both by production of binding sites at the mem-
brane and by phosphorylation, whereas GRP-1 might be
regulated solely by the availability of membrane-binding
sites. These exchange factors might thus be uniquely
modulated by a variety of signal pathways linking extra-
cellular cues to changes in the actin cytoskeleton, mem-
brane trafficking events or both.
Materials and methods
Materials
PC (1,2-dioleoyl-sn-glycero-3-phosphocholine) and PS (1,2-dioleoyl-
sn-glycero-3-phospho-L-serine) were from Avanti Polar Lipids;
PI(3,4,5)P3 (dipalmitoyl-phosphatidylinositol tris-3,4,5-phosphate) from
Matreya Inc; PI(4,5)P2 (L-α-phosphatidyl-D-myo-inositol-4,5-bisphos-
phate) and FuGENE 6 from Boehringer Mannheim; radiolabeled com-
pounds from NEN Life Science; and PKC (calcium-dependent and
lipid-dependent α, β and γ isoforms) from Biomol. The rabbit polyclonal
antiserum to ARNO has been described previously [5].
Liposome production
Liposomes containing either PI(4,5)P2 or PI(3,4,5)P3 (PC:PS:PIPs
65:30:5 w:w) or no phosphoinositols (PC:PS 70:30) were made by
drying lipids out of chloroform under a stream of nitrogen. Dried
lipids were resuspended in 20 mM Tris pH 7.5, 120 mM NaCl and
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Figure 3
In vivo phosphorylated ARNO is selectively located in the cytosol.
(a) HeLa cells expressing Myc–ARNO and labeled with 32P as
described in the Materials and methods were incubated in the
presence (+) or absence (–) of 500 nM PMA for 20 min. Cells were
lysed and separated into cytosol and membranes, and ARNO
immunoprecipitated with rabbit anti-ARNO polyclonal antiserum. After
separation by SDS–PAGE and transfer to nitrocellulose, radiolabeled
ARNO was visualized by autoradiography (lower panel) and western
blotting with monoclonal anti-Myc antibody (9E10, upper panel).
(b) The S392E mutation reduces ARNO membrane association. HeLa
cells expressing Myc-tagged wild-type (WT) ARNO or the S392E
mutant were fractionated as described in the Materials and methods.
ARNO was localized by western blotting with 9E10 antibody. Data
shown are representative of multiple experiments.
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freeze-thawed four times, then extruded through 0.45 µM durapore-
PVDF filters (Millipore). Vesicles used in lipid-binding experiments
also contained [3H]PC (1.5–2.5 µCi/mg lipid).
Recombinant protein production
His6-tagged ARNO proteins were produced as described previously
[6]. Myristoylated ARF6 was produced according to Randazzo et al.
[20] with the addition of a Sephacryl S-200 gel filtration column as a
final step.
Guanine nucleotide exchange
ARNO (100 nM) was incubated with PKC (1.1 ng/µl) in the presence
or absence of 200 µM ATP in 20 mM Tris pH 7.5, 60 mM NaCl, 5 mM
MgCl2, 250 µM CaCl2, 0.125% BSA, 0.5 mM β-mercaptoethanol,
1 µM PMA and 0.4 mg/ml PI(4,5)P2-containing liposomes at 22°C for
30 min. Exchange was then tested by incubating 10 nM ARNO with
187.5 nM myristoyl-ARF6, 400 nM [35S]GTPγS (1.875 Ci/mol) and
0.2 mg/ml liposomes in 20 mM Tris pH 7.5, 1.5 mM MgCl2, 75 µM
CaCl2, 100 mM NaCl, 15 µM β-mercaptoethanol at 37°C. At various
times, aliquots containing 5.6 pmol ARF6 were removed and exchange
stopped by dilution into ice-cold 20 mM Hepes pH 7.4, 10 mM MgCl2,
100 mM NaCl. The amount of [35S]GTPγS bound to ARF was deter-
mined by a nitrocellulose filter-binding assay.
Lipid binding
ARNO (5 µg, 50 µg/ml), liposomes (0.4 mg/ml) and PKC (0.525 ng/µl)
were incubated in the presence or absence of 100 µM ATP in 20 mM
Tris pH 7.5, 1.5 mM MgCl2, 75 µM CaCl2, 100 mM NaCl, 15 µM β-mer-
captoethanol, and 1 µM PMA for 15 min at 37°C. ARNO and bound
liposomes were then isolated by binding to Ni-NTA agarose at 4°C, and
washed with cold 20 mM Tris pH 7.5, 120 mM NaCl. The amount of
lipid bound to ARNO was quantitated by liquid scintillation counting.
Subcellular distribution of phosphorylated ARNO
HeLa cells were transiently transfected with plasmid expressing
Myc–ARNO using FuGENE 6. After overnight incubation in low-serum
media (0.5% FBS), cells were phosphate-starved for 2 h in phosphate-
free MEM, and labeled for 3 h with 32P-orthophosphate (0.5 mCi/ml)
followed by treatment 500 nM PMA. Cells were lysed and fractionated
according to Fleming et al. [21]. ARNO was immunoprecipitated with
polyclonal rabbit anti-ARNO antiserum and analyzed for the presence
of 32P-ARNO as previously described [6].
Subcellular distribution of S392E ARNO
Plasmids expressing Myc–ARNO lacking the coiled-coil domain either
with or without the S392E mutation were transfected into HeLa cells
using FuGENE6. Cytosolic and membrane fractions from cells express-
ing equivalent amounts of ARNO were isolated as described by Nagel
et al. [9]. Total protein was isolated [22] and analyzed by western blot
with monoclonal anti-Myc antibody 9E10.
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